Biography
Dr. Hatch has been a faculty physician with UTMB for over ten years, specializing in breast and gynecological cancers. She is board certified in Radiation Oncology by the American Board of Radiology (ABR) and an active member with the American Society for Therapeutic Radiology & Oncology (ASTRO). She received her doctorate in medicine from the University of Texas Health Science Center at Houston, TX and completed her residency in radiation therapy at Baylor College of Medicine as chief resident. Before entering medical school, Dr. Hatch received her degree in engineering from Tennessee Technological University, which served as a solid foundation for the technological demands found in the field of radiotherapy.
Research Interest
Oxidative damage in benign endometrial tissue especially as it relates to neoplastic induction Cancer cachexia Treatment related toxicities Gynecologic malignancy in the senior oncology patient And Financial burden of cancer care
Biography
Dr. Sherry Bradford attended undergraduate school at SUNY at Buffalo and was awarded a full tuition scholarship to pursue her PhD graduate degree (Biochemistry) from the University of Buffalo/ Roswell Park Cancer Institute Division of SUNY at Buffalo School of Medical and Biomedical Sciences. During her clinical laboratory vocation, she was solicited by the Chief of Surgery at Millard Fillmore Hospital, Buffalo, NY, to direct the Surgical Research laboratory. There she successfully led the research on the use of human micro vascular umbilical cord endothelium for lining stents. It was while Sherry was at Millard Fillmore Hospital, that she was awarded the “1st Place - Award for Excellence in Research†from the American Federation for Clinical Research In 1997, Dr. Bradford was approached by the Department of Pharmacokinetics, at Millard Fillmore Hospital, to lead their newly formed Pharmacokinetics Oncology Department. As the Principal Investigator, she was charged with the responsibility to develop an in vitro chemo sensitivity test on tumor cells using the flow cytometer. In 2008, Dr Bradford and colleagues form AccuTheranostics and the idea on Oncology Personalized Medicine based on the specific patient’s own biochemical and genetic profile to administer Personalized treatment regimens.Currently, Dr. Bradford sits on the EDITORIAL BOARD of the International Journal of Medical and Health Sciences Research; commence on July 20 2014; and on the EDITORIAL BOARD of Insights in Cancer Research, and has authored and co-authored a number of scientific peer-reviewed manuscripts.She is also a member of many professional organizations including (but not limited to): International Metabolic Cancer Group, AACR, ASCO, and GLIFCA.
Research Interest
Research interest includes human microvascular umbilical cord endothelium and in Pharmacokinetics Oncology
Biography
Dr. Concepcion Diaz-Arrastia received her medical education from UMDNJ-Rutgers Medical School, and completed residency and fellowship training at State University of New York Downstate Medical Center in 1994. She is board certified in obstetrics, gynecology and gynecologic oncology. As a leader in the implementation of new surgical techniques like the computer-enhanced (robotic) surgery in gynecology, Dr. Arrastia was the first to report that hysterectomies could be performed using the DaVinci system in 2002. Likewise, she was the first physician in Texas to perform fertility-preserving radical vaginal trachelectomy surgery for invasive cervical carcinoma. Dr. Arrastia strongly supports early diagnosis through universal cancer screening. As Medical Director of the non-profit organization, Dia de la Mujer Latina, she has undertaken the task of bridging the gap for those women in the medically underserved communities to have easy access to cancer screening.
Research Interest
Her research interests include developing molecular signatures of cervical cancer risk. She has served as Principal Investigator for several NIH funded translational research projects in HPV-associated cervical neoplasia with the goal of developing robust prognostic and diagnostic biomarkers for refining the pathological staging of cervical carcinoma. The ultimate objectives of Dr. Arrastia’s research are personalization of care optimizing treatment outcome, while minimizing adverse reactions.
